CYPH Stock: Cypherpunk Technologies Inc. Stock Price, Analysis & Insights
Get live cyph stock price $2.75, comprehensive Cypherpunk Technologies Inc. stock analysis, charts, news, and expert forecast. Real-time cyph stock data and investment insights.
Loading chart...
Company Overview
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Company Information
- CEO
- Douglas E. Onsi
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 52
Contact Information
- Website
- https://www.leaptx.com
- Address
- 47 Thorndike Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.09) may provide portfolio stability
Business Model & Strategy
Cypherpunk Technologies Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Douglas E. Onsi, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Cypherpunk Technologies Inc. competes in the Biotechnology within the broader Healthcare. With 155.8 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Cypherpunk Technologies Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Cypherpunk Technologies Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Cypherpunk Technologies Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Cypherpunk Technologies Inc.
- ⚠Investors should consider how Cypherpunk Technologies Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
155.79M
P/E Ratio
-1.74
Beta
0.09
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 155.79M market capitalization
- Trading Volume: 263.22M shares traded today
- Price Range: 52-week range of $0.22 - $3.58
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc. (CYPH) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 155.79M, the company represents a significant player in its market. The stock is currently trading at $2.75 with a positivedaily change of 56.25%.
The company's 52 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.74, beta of 0.09, and 52-week price range from $0.22 to $3.58when evaluating investment opportunities.
Why Invest in Cypherpunk Technologies Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Douglas E. Onsi
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.